Disease recurrence and progression remain as significant challenges for the management of non-muscle invasive bladder cancer (NMIBC). In recent years, novel drugs and delivery systems have been investigated as strategies to reduce recurrence, progression and mortality. In this review, we focus on the role of intravesical hyperthermic chemotherapy and discuss a novel approach involving a heat-activated drug delivery system (ThermoDox) that enables local accumulation of systemic chemotherapy.
|Original language||English (US)|
|Number of pages||6|
|Journal||Archivos Espanoles de Urologia|
|State||Published - May 2018|
All Science Journal Classification (ASJC) codes